Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer

Journal of Clinical Oncology

Volumn 22, Issue 12, 2004, Pages 2284-2293

  Ayers, M ^a   Symmans, W F ^a   Stec, J ^a   Damokosh, A I ^a   Clark, E ^a   Hess, K ^a   Lecocke, M ^a   Metivier, J ^a   Booser, D ^a   Ibrahim, N ^a   Valero, V ^a   Royce, M ^a   Arun, B ^a   Whitman, G ^a   Ross, J ^a   Sneige, N ^a   Hortobagyi, G N ^a   Pusztai, L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; RNA; ANTINEOPLASTIC AGENT; CAF PROTOCOL;

ACCURACY; AMINO ACID SEQUENCE; ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MOLECULAR CLONING; MOLECULAR MODEL; MULTIGENE FAMILY; PREDICTION; PRIORITY JOURNAL; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VALIDATION PROCESS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; BREAST TUMOR; FEASIBILITY STUDY; GENETICS; MIDDLE AGED; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEASIBILITY STUDIES; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; PROGNOSIS; TREATMENT OUTCOME;

EID: 2942729848     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.05.166     Document Type: Article

References (29)

1. Carlson RW, Andersen BO, Bensinger W, et al: NCCN practice guidelines for breast cancer. Oncology 14:33-49, 2000
2. National Institutes of Health Consensus Development Conference, November 2, 2000. http://www.consensus.nih.gov
3. Rivera E, Holmes FA, Frye D, et al: Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer 89:2195-2201, 2000
4. Henderson IC, Berry D, Demetri G, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
5. Bast RC, Ravdin P, Hayes DF, et al: 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-1878, 2001
6. Hortobagyi GN, Hayes D, Pusztai L: Integrating newer science into breast cancer prognosis and treatment: Molecular predictors and profiles. American Society of Clinical Oncology 2002 Annual Meeting Summaries 191-202, 2002
7. van't Veer LJ, Dai H, van de Vijver, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
8. Pomeroy SL, Tamayo P, Gaasenbeek M, et al: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415:436-442, 2002
9. Shipp MA, Ross KN, Tamayo P, et al: Diffuse large B-cell lymphoma outcome prediction by gene expression profiling and supervised machine learning. Nat Med 8:68-74, 2002
10. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
11. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
12. Chiang LW, Grenier JM, Ettwiller L, et al: An orchestrated gene expression component of neuronal programmed cell death revealed by cDNA array analysis. Proc Natl Acad Sci U S A 98:2814-2819, 2001
13. Pusztai L, Ayers M, Stec J, et al: Gene expression profiles obtained from single passage fine needle aspirations (FNA) of breast cancer reliably identify prognostic/predictive markers such as estrogen (ER) and HER-2 receptor status and reveal large scale molecular differences between ER-negative and ER-positive tumors. Clin Cancer Res 9:2406-2415, 2003
14. Symmans WF, Pusztai L, Ayers M, et al: Total RNA yield and microarray gene expression profiles from fine needle aspiratons and core needle biopsy samples of breast cancer. Cancer 97:2960-2971, 2003
15. Hwang D, Schmitt WA, Stephanopoulos G, et al: Determination of minimum sample size and discriminatory expression patterns in microarray data. Bioinformatics 18:1184-1193, 2002
16. Mukherjee S, Tamayo P, Rogers S, et al: Estimating dataset size requirements for classifying DNA microarray data. J Comput Biol 10: 119-142, 2003
17. Golub TR, Slonim DK, Tamayo P, et al: Molecular classification of cancer: Class discovery and class predication by gene expression monitoring. Science 286:531-537, 1999
18. Vapnik VN: Statistical Learning Theory. New York, NY, Wiley, 1998
19. Mukherjee S, Tamayo P, Slonim D, et al: (2000) Support vector machine classification of micro array data. MIT Report AI Laboratory and Center for Biological Computational Learning. AI Memo NO 1667 CBCL, Paper No. 82
20. Green MC, Buzdar AU, Smith T, et al: Weekly paclitaxel followed by FAC in the neoadjuvant setting provides improved pathological complete remission rates compared to standard paclitaxel followed by FAC therapy: Preliminary results of an ongoing prospective randomized trial. Proc Am Soc Clin Onc 20:33a, 2001 (abstr 129)
21. NCBI LocusLink Web site, Gene symbol and ontology, http://www.ncbi.nlm. nih.gov/LocusLink
22. NSABP: The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: Preliminary results from NSABP Protocol B-27. Breast Cancer Res Treat 69:210, 2001 (abstr 5)
23. Smith IC, Heys SD, Hutcheon AW, et al: Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466, 2002
24. Kocher O, Comelia N, Gilchrist A, et al: PDZK1, a novel PDZ domain-containing protein up-regulated in carcinomas and mapped to chromosome 1q21, interacts with cMOAT (MRP2), the multidrug resistance-associated protein. Lab Invest 79:1161-1170, 1999
25. Kocher O, Cheresh P, Lee SW, et al: Identification and partial characterization of a novel membrane-associated protein (MAP17) up-regulated in human carcinomas and modulating cell replication and tumor growth. Am J Pathol 149:493-500, 1996
26. Jauliac S, Lopez-Rodriguez C, Shaw LM, et al: The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol 4:540-544, 2002
27. Anderson P, Caligiuri M, O'Brien C, et al: Fc-gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. Proc Natl Acad Sci U S A 87:2274-2278, 1990
28. Zaks-Zilberman M, Zaks TZ, Vogel SN: Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine 15:156-165, 2001
29. Oliver J, Gruss, Rafael E, et al: Ran induces spindle assembly by reversing the inhibitory effect of importin α on TPX2 activity cell. 104:83-93, 2001